DÜSSELDORF / LONDON (IT BOLTWISE) – Vidac Pharma is planning an IPO on the Düsseldorf Stock Exchange to increase the liquidity of its shares. The company, which specializes in innovative oncological treatments, sees this as an important step towards expanding its investor base. The listing is scheduled to take place at the beginning of November and complements the existing listings in Hamburg, Stuttgart and Berlin.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
Vidac Pharma, a biopharmaceutical company specializing in the development of innovative oncology and oncodermatology treatments, is planning an IPO on the Düsseldorf Stock Exchange. This strategic decision aims to increase stock liquidity and improve trading opportunities. The move is seen as crucial in paving the way for future trading via XETRA.
The listing on the Düsseldorf stock exchange, which is planned for the beginning of November, complements the existing listings in Hamburg, Stuttgart and Berlin. Dr. Max Herzberg, CEO of Vidac Pharma, emphasizes the importance of these steps to improve liquidity and expand the investor base. The company hopes to use these measures to strengthen its position in the market and attract new investors.
Vidac Pharma is in the clinical phase and is committed to developing treatments that specifically alter the tumor environment. Their candidate VDA-1102 is an example of these innovative approaches that raise hope for advances in cancer therapy. However, the realization of the stock exchange project still depends on the approval of the Düsseldorf Stock Exchange, which is why the company cannot provide any guarantees.
The decision to list in Düsseldorf is part of a broader strategy aimed at increasing Vidac Pharma’s visibility and attractiveness on the capital market. Industry experts see this step as an opportunity to strengthen the company’s financial base and advance the development of new therapies. However, the uncertainties and risks associated with such forward-looking statements should not be underestimated.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Vidac Pharma plans to go public in Düsseldorf to increase liquidity”.